Class II โ€” Potential Health Hazard

Potential health hazard โ€” use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

Metformin Hydrochloride Extended-Release Tablets USP Recalled by Granules Pharmaceuticals Inc Due to CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity...

Date: July 3, 2020
Company: Granules Pharmaceuticals Inc
Status: Ongoing
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Granules Pharmaceuticals Inc directly.

Affected Products

Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, a) 100 ct. bottle (NDC 70010-492-01) and 500 ct. bottle (NDC 70010-492-05), Manufactured for: Granules Pharmaceutical Inc., Chantilly, VA, Manufactured by: Granules India Limited, Hyderabad - 500-081, India

Quantity: a) 476,073 bottles; b) 2,100 bottles

Why Was This Recalled?

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Where Was This Sold?

This product was distributed nationwide across all 50 states.

Affected (51 states)Not affected

About Granules Pharmaceuticals Inc

Granules Pharmaceuticals Inc has 1 total recall tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report